Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$27 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.8
Industry P/E
--
EV/EBITDA
1.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$0.7
EPS
$-0.8
Face value
--
Shares outstanding
6,373,915
CFO
$-164.96 Mln
EBITDA
$-169.96 Mln
Net Profit
$-173.68 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exicure (XCUR)
| -21.5 | 13.7 | -21.5 | -67.8 | -0.8 | -58.3 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Exicure (XCUR)
| -60.4 | 365.5 | -49.6 | -81.0 | -88.6 | -38.1 | -19.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Exicure (XCUR)
|
4.3 | 26.7 | 0.0 | -5.0 | -- | -92.5 | -- | 6.8 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City,... California. Read more
CEO & Director
Mr. Paul Kang
CEO & Director
Mr. Paul Kang
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Exicure Inc (XCUR) is $4.25 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Exicure Inc (XCUR) has given a return of -0.79% in the last 3 years.
Since, TTM earnings of Exicure Inc (XCUR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.58
|
8.28
|
|
2024
|
-2.82
|
4.04
|
|
2023
|
-0.07
|
0.38
|
|
2022
|
-0.45
|
0.08
|
|
2021
|
0.00
|
0.02
|
The 52-week high and low of Exicure Inc (XCUR) are Rs 13.74 and Rs 3.42 as of 05-Apr-2026.
Exicure Inc (XCUR) has a market capitalisation of $ 27 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Exicure Inc (XCUR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.07
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.